In Stunning Turnaround, Embattled Tenapanor Gets FDA Approval Following CRL

It’s rare, but it turns out a company seeking approval for a new indication can find success in the wake of an FDA Complete Response Letter (CRL) as is the case for Ardelyx’s Xphozah (tenapanor).
Source: Drug Industry Daily

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.